HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Apr.22) - TCM VBP Results, R&D Thinking Mode, Biotech Delisting

Autobio Diagnostics Co Ltd (603658.CH) - Logic Changes

Pre-IPO Scivita Medical Technology - The Industry, the Business, and the Concerns

The Impact of America COMPETES Act on China Healthcare – Supply Chain Decoupling?

Chongqing Zhifei Biological Products (300122.CH) - WHO's One-Dose HPV Vaccine Regimen & The Outlook

Sino Biopharmaceutical (1177.HK) - Three “Golden Eggs” and the Risks Behind

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Shijiazhuang Yiling Pharmaceutical / Equity Bottom-Up

Shijiazhuang Yiling Pharmaceutical (002603 CH)

<ul>
<li>There are doubts about the efficacy of Lianhua Qingwen to treat mild cases of COVID-19 in China, leading to the plunge of Yiling’s share price.</li>
<li>Fully evaluating the efficacy of Lianhua Qingwen requires larger double-blind randomized clinical trials. Data from other than double-blind controlled clinical trials are hard to be conclusive and can be controversial.</li>
<li>Even if Yiling could escape unscathed from the controversy, Yiling’s achievements since 2020 in capital market may not have sustainability.Together with the potential risks, investors are advised to remain cautious.</li>
</ul>


There are doubts about the efficacy of Lianhua Qingwen to treat mild cases of COVID-19 in China, leading to the plunge of Yiling’s share price.
Fully evaluating the efficacy of Lianhua Qingwen requires larger double-blind randomized clinical trials. Data from other than double-blind controlled clinical trials are hard to be conclusive and can be controversial.
Even if Yiling could escape unscathed from the controversy, Yiling’s achievements since 2020 in capital market may not have sustainability.Together with the potential risks, investors are advised to remain cautious.


Shijiazhuang Yiling Pharmaceutical (002603.CH) - Doubts About COVID-19 Drug and the Concerns Behind